Duality Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs), has successfully passed the Hong Kong Stock Exchange (HKEX) listing hearing and disclosed its post-hearing information on March 23. Morgan Stanley, Jefferies, and CITIC Securities Company Limited are serving as joint sponsors for the IPO.<\/p>\n\n\n\n
Pipeline and Core Products<\/strong> Duality Bio’s core products, DB-1303\/BNT323 and DB-1311\/BNT324, are leading the charge. DB-1303\/BNT323, a late-stage HER2 ADC candidate, is currently undergoing two registration trials and one global potential registration study, with the first indication (HER2-expressing endometrial cancer, EC) expected to file for accelerated approval with the FDA as early as 2025. According to Frost & Sullivan, DB-1303 is the global clinical leader for treating HER2-expressing EC and is also a leading candidate for treating low HER2-expressing breast cancer (BC), with potential to expand into other unmet cancer indications.<\/p>\n\n\n\n DB-1311\/BNT324, a leading B7-H3 ADC candidate globally, is being studied as a potential second-line (or later) treatment for metastatic castration-resistant prostate cancer (mCRPC) and small cell lung cancer (SCLC) patients, with potential to expand into front-line combination therapies.<\/p>\n\n\n\n
Founded in 2019, Duality Bio is dedicated to developing ADCs for patients with cancer and autoimmune diseases. The company has established a robust pipeline of 12 self-developed ADC candidates, including seven in clinical stages, two next-generation bispecific ADCs expected to enter clinical trials between 2025 and 2026, and several other preclinical ADCs.<\/p>\n\n\n\n